SCHEMBL1031402

SCHEMBL1031402

ClCCCCc1nnnn1C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
MAPT P10636 2/20 0.55
TP53 P04637 1/20 0.55
TSHR P16473 4/20 0.48
PDE3B Q13370 3/20 0.48
PDE3A Q14432 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
LMNA P02545 2/20 0.48
KMT2A Q03164 2/20 0.48
ABCC4 O15439 1/20 0.48
CACNA1F O60840 1/20 0.48
ABCB11 O95342 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAPK1 P28482 1/20 0.48
THPO P40225 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7318244 0.95 ALDH1A1 (0.56) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL5135783 0.84 ALDH1A1 (0.55) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL6075649 0.84 ALDH1A1 (0.55) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL6075225 0.84 ALDH1A1 (0.55) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL14506177 0.84 ALDH1A1 (0.55) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL10468251 0.83 ALDH1A1 (0.54) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL7311249 0.83 ALDH1A1 (0.56) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL3091610 0.82 ALDH1A1 (0.63) ALDH1A1MAPTTP53TSHRNPSR1
SCHEMBL10676652 0.80 L3MBTL1 (0.52) ALDH1A1MAPTTP53TSHRPDE3B
SCHEMBL9204714 0.79 ALDH1A1 (0.59) ALDH1A1MAPTTP53TSHRPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117105879-A Synthesis method of 5- (4-chlorobutyl) -1-cyclohexyl-1, 2,3, 4-tetrazole 河北科技大学 2023-11-24 CN claimed
CN-111233777-A Synthesis method of N-cyclohexyl-5- (4-chlorobutyl) -1H-tetrazole 上海立科药物化学有限公司 2020-06-05 CN claimed
CN-109776498-B Preparation method of cilostazol 浙江永宁药业股份有限公司 2020-04-07 CN claimed
CN-110685047-A High-elasticity sewing thread 佛山金丝路线业有限公司 2020-01-14 CN claimed
CN-107325078-B Preparation method of cilostazol 烟台万润药业有限公司 2020-01-07 CN claimed
CN-107382970-A A kind of synthetic method of Cilostazol 浙江金立源药业有限公司 2017-11-24 CN claimed
CN-105111190-B A kind of synthetic method of Cilostazol 浙江金立源药业有限公司 2017-11-07 CN claimed
CN-107325078-A A kind of preparation method of Cilostazol 烟台万润药业有限公司 2017-11-07 CN claimed
CN-105111190-A Method for synthesizing cilostazol ZHEJIANG KINGLYUAN PHARMACEUTICAL COMPANY LTD 2015-12-02 CN claimed
US-7825251-B2 Process for producing carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-11-02 US claimed
CN-1733743-A N-cyclohexyl-5-(4-chlorobutyl)-1H-tetrazole synthesis method SHANGHAI RECORD PHARMACEUTICAL (CN) 2006-02-15 CN claimed
US-20050222202-A1 Highly pure cilostazol and an improved process for obtaining same PERRIGO API LTD. (IL) 2005-10-06 US claimed
US-20050101631-A1 Process for producing carbostyril derivatives OTSUKA PHARMACEUTICALS COMPANY 2005-05-12 US claimed
EP-1311485-A4 PROCESSES FOR PREPARING CILOSTAZOL TEVA PHARMA (IL) 2004-05-12 EP claimed
US-20040059117-A1 Process for producing carbostyril derivatives OTSUKA PHARMACEUTICALS COMPANY 2004-03-25 US claimed
CN-1469864-A Process for preparing cilostazol ������ҩ��ҵ���޹�˾ 2004-01-21 CN claimed
EP-1311485-A1 PROCESSES FOR PREPARING CILOSTAZOL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-05-21 EP claimed
US-6515128-B2 Dissolving 6-hydroxy-3,4-dihydroquinolinone and a base in water; dissolving a 1-cyclohexyl-5- (4-halobutyl)-tetrazole in water-immiscible solvent, mixing aqueous phase and organic phase in presence of phase transfer catalyst; recovering TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-02-04 US claimed
US-20020099213-A1 Processes for preparing cilostazol TEVA PHARMACEUTICALS USA, INC. 2002-07-25 US claimed
WO-2002014283-A1 PROCESSES FOR PREPARING CILOSTAZOL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2002-02-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222202-A1 Highly pure cilostazol and an improved process for obtaining same PDE7A, PDE8B, PDE9A ALDH1A1 1905/4885MAPT 4246/4885TP53 4592/4885
US-20040059117-A1 Process for producing carbostyril derivatives PTGIR, PTGIS, F2R ALDH1A1 670/4885MAPT 2081/4885TP53 4834/4885
US-20020099213-A1 Processes for preparing cilostazol PDE3A, PDE12, PDE5A ALDH1A1 2070/4885MAPT 3372/4885TP53 4384/4885
US-20050101631-A1 Process for producing carbostyril derivatives PTGIR, PTGIS, PLAT ALDH1A1 1969/4885MAPT 1693/4885TP53 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.